New Journey Health Technology Group Co Ltd
New Journey Health Technology Group Co Ltd operates in the health care providers and services sector, generating revenue through health-related services and products.
Business. New Journey Health Technology Group Co Ltd operates in the health care providers and services sector, generating revenue through health-related services and products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
New Journey Health Technology Group Co Ltd operates in the health care providers and services sector, generating revenue through health-related services and products.
New Journey Health Technology Group Co Ltd maintains a capital structure characterized by significant leverage and tight liquidity. The company reports total assets of CNY 6.65 billion against total liabilities of CNY 4.69 billion, resulting in total equity of CNY 1.95 billion. Long-term debt stands at CNY 2.36 billion, yielding a debt-to-equity ratio of 1.21. Liquidity is constrained, evidenced by a current ratio of 0.54, which indicates that current liabilities exceed current assets. The risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt. Operating cash flow is positive at CNY 293.8 million, but free cash flow is negative at CNY -123.9 million due to capital expenditures of CNY 257.0 million.
Profitability metrics suggest modest returns on capital. The company generated net income of CNY 30.9 million on revenue of CNY 3.05 billion, resulting in a net margin of approximately 1.0%. Return on equity is 5.94%, and return on assets is 1.75%. These returns are generated against a valuation multiple of 55.03x P/E and 3.27x P/B. The EV/EBITDA multiple is 51.48x, and EV/Revenue is 2.24x. Without cohort median data provided in the input, direct comparative analysis of profitability efficiency is omitted, but the absolute returns indicate low leverage-adjusted profitability.
- Liquidity is tight with a current ratio of 0.54 and negative net cash after debt, posing medium liquidity risk.
- Leverage is elevated with a debt-to-equity ratio of 1.21 and long-term debt of CNY 2.36 billion.
- Profitability is thin with a net margin of ~1.0% and ROE of 5.94%, despite a high P/E multiple of 55.03x.
- Free cash flow is negative at CNY -123.9 million due to capital expenditures exceeding operating cash flow.
- Dilution risk is low as basic and diluted share counts are identical.
Bull / Bear case
Generated · model-assistedCash conversion ratio of 2.77 ranks in the top quartile, suggesting superior efficiency in converting earnings to cash.
Dilution risk is assessed as low, providing some protection for existing shareholders against equity value erosion.
Credit risk is flagged as high, indicating significant potential for financial distress or default on obligations.
Debt-to-equity ratio of 1.21 sits in the bottom quartile, reflecting excessive leverage compared to peer median of 0.4.
In focus — financials by report
Revenue ¥3.91B, +23,8% YoY; Operating income −81,7% YoY.
- ▍Revenue ¥3.91B, +23,8% YoY
- ▍Operating income −81,7% YoY
- ▍Net income −81,4% YoY
- ▍Free cash flow +77,1% YoY
- ▍Net margin 0.7%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Ev To Operating Incomeenterprise_value / operating_income
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Enterprise Valuemarket_cap - net_cash
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Capmarket_price * shares_outstanding_diluted
- New Journey Health Technology Group Co Ltd Market data — financials · 2026-07-06